Actively Recruiting
Study of SHR-1316 Antibody or Placebo with Chemotherapy for Treating Resectable Stage II or III Non-Small Cell Lung Cancer
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2021-11-04
537
Participants Needed
7
Research Sites
191 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of the monoclonal antibody SHR-1316 combined with platinum doublet chemotherapy for patients with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer NSCLC. This study aims to assess the efficacy, safety, and immune response triggered by this neoadjuvant treatment followed by adjuvant SHR-1316 or placebo, to improve treatment outcomes. The trial is a randomized, double-blind, multicenter Phase IbIII clinical study sponsored by Jiangsu HengRui Medicine Co., Ltd. Participants receive SHR-1316 or placebo together with chemotherapy drugs such as carboplatin and albumin-bound paclitaxel during the neoadjuvant phase, consisting of three 21-day cycles. This is followed by an adjuvant phase where SHR-1316 or placebo is administered for up to 16 cycles. The chemotherapy drugs are given intravenously on specified days within each cycle, while SHR-1316 or placebo is delivered as an intravenous infusion on Day 1 of each cycle. During the trial, participants will undergo surgery after the neoadjuvant treatment and will be monitored for major pathological response, event-free survival, overall survival, complete pathological response, objective response rate, and disease-free survival at various time points up to approximately 96 months. Researchers will also evaluate tumor tissue for PD-L1 expression and assess organ function, safety, and immune response throughout the study. The total duration of participation may extend over several years to fully assess long-term outcomes.
CONDITIONS
Brief Title
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Research Team
V
Vivian Shi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here